Scholarlink

<p>Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, with rising incidence. While most CSCCs are cured with surgical intervention, a subset will develop poor outcomes. Despite its prevalence, CSCC is excluded from national cancer registries in the United States and many other countries. This poses a significant challenge, as most CSCC studies are single or dual-center retrospective cohort studies with small sample sizes or based on European registries. To address this barrier, 12 institutions in the United States, Spain, and Brazil pooled retrospective tumor data to establish the largest CSCC cohort to date with 23,166 tumors. In this protocol, we provide detailed methods and cohort information for this pooled database. Of the 12 centers, 10 are in the United States, 1 is in Spain, and 1 is in Brazil; this includes 10 academic centers, 1 private practice, and 1 private philanthropic hospital. Patient information (demographics and immunosuppression status), tumor details, treatment history, disease outcomes, and follow-up duration were collected. We present inclusion and exclusion criteria for each of the 12 centers, including date ranges, age restrictions, and follow up specifications. Three centers only included tumors treated with Mohs surgery, and 1 center only included tumors treated with excision. One site included only head and neck tumors, and 8 centers excluded mucosal and genital tumors. Five institutions included only higher risk CSCCs, with varying definitions. Disease outcomes included local recurrence, nodal metastasis, satellite/in-transit metastasis, distant metastasis, disease-specific death, and overall mortality. This multi-institutional, international database is a significant step forward in refining our understanding of CSCC, as it has the largest sample size to date allowing for analyses with improved power and external validity. Multiple analyses utilizing this pooled dataset are currently underway. This published protocol with detailed methods and cohort information will enhance the transparency and interpretation of these studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protocol for establishing a large, international, multicenter cutaneous squamous cell carcinoma database

  • 期刊论文

  • 发表日期：

    2025年7月10日

查看全文
  • Diana Hallak,
  • Emily Ruiz,
  • Nina Ran,
  • Emily E. Granger,
  • Anokhi Jambusaria-Pahlajani,
  • Shlomo Koyfman,
  • Allison Vidimos,
  • Ashley Wysong,
  • Kelsey Hirotsu,
  • John A. Carucci,
  • Joi B. Carter,
  • Javier Cañueto,
  • Fabio Muradás Girardi,
  • Aaron R. Mangold,
  • David G. Brodland,
  • John A. Zitelli,
  • Tyler J. Willenbrink,
  • Divya Srivastava,
  • Rajiv I. Nijhawan,
  • David R. Carr,
  • Kathryn T. Shahwan

摘要

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, with rising incidence. While most CSCCs are cured with surgical intervention, a subset will develop poor outcomes. Despite its prevalence, CSCC is excluded from national cancer registries in the United States and many other countries. This poses a significant challenge, as most CSCC studies are single or dual-center retrospective cohort studies with small sample sizes or based on European registries. To address this barrier, 12 institutions in the United States, Spain, and Brazil pooled retrospective tumor data to establish the largest CSCC cohort to date with 23,166 tumors. In this protocol, we provide detailed methods and cohort information for this pooled database. Of the 12 centers, 10 are in the United States, 1 is in Spain, and 1 is in Brazil; this includes 10 academic centers, 1 private practice, and 1 private philanthropic hospital. Patient information (demographics and immunosuppression status), tumor details, treatment history, disease outcomes, and follow-up duration were collected. We present inclusion and exclusion criteria for each of the 12 centers, including date ranges, age restrictions, and follow up specifications. Three centers only included tumors treated with Mohs surgery, and 1 center only included tumors treated with excision. One site included only head and neck tumors, and 8 centers excluded mucosal and genital tumors. Five institutions included only higher risk CSCCs, with varying definitions. Disease outcomes included local recurrence, nodal metastasis, satellite/in-transit metastasis, distant metastasis, disease-specific death, and overall mortality. This multi-institutional, international database is a significant step forward in refining our understanding of CSCC, as it has the largest sample size to date allowing for analyses with improved power and external validity. Multiple analyses utilizing this pooled dataset are currently underway. This published protocol with detailed methods and cohort information will enhance the transparency and interpretation of these studies.